Depth bar: Faridabad-pin dossier for a large pharma group whose factory is not in Faridabad. Plot 74 is a marketing office. Bill on that plot is a tiny DHBVN LT number. Use [~] for estimates, [dir] for directories, [!] for unverified claims. Visit-week action is qualify-first, not a 60-Day Proof walk.

1. Company overview & snapshot

United Biotech Private Limited (UBPL, trading as United Biotech India) is a 1997-founded pharmaceutical formulation company. Public pages lead with WHO-cGMP and ISO 9001:2015, oncology and specialty injectables, lyophilised products, pre-filled syringes and orals, and export language covering 60+ countries. The WhatsApp / extras pin “United biotech” lands in Faridabad. That pin is Umano Healthcare Pvt Ltd, a 100% subsidiary at Plot 74, Sector 27-A — a marketing and office address, not a filling hall. The factory is Bagbania, Baddi-Nalagarh Road, Solan HP. Stamped’s Faridabad week should treat this as a geo/entity trap, not a plant walk.

1.1 Legal identity & corporate structure

Legal name: United Biotech Private Limited. CIN U24239DL1997PTC084814, incorporated 31 January 1997, ROC Delhi, Active, unlisted. MCA registered address commonly cited as E-142, Saket, New Delhi 110017. Operating HO on the company site: FC/B1 Extn, Mohan Co-operative Industrial Estate, Mathura Road, New Delhi 110044. Authorised capital ₹5.0 Cr, paid-up ~₹4.54 Cr [dir]. Directors on Tofler-style extracts: Ashwani Kumar, Rajiv Kumar, Sanjeev Kumar. Last reported AGM in aggregator snapshots: 30 September 2024.

Faridabad legal entity (the pin): Umano Healthcare Private Limited, CIN U24297DL2011PTC227673, GST 06AABCU3733E1ZN [dir]. IndiaMART / CB Insights place it at Plot 74, Sector 27-A, Main Mathura Road, Faridabad 121003 (CB Insights notes opposite Sector 28 Metro). Umano pages and IndiaMART describe it as established ~2013 under United Biotech, selling pain, bone/joint, women’s health, GI and general supplements. IndiaMART GST partners include Ashwani, Sanjeev, Rajiv Kumar and Kailash Devi; CEO listed as Mansi Sharma [dir]. Umano paid-up capital ~₹10 Cr [dir]; annual turnover band ₹5–25 Cr [dir] / ~₹10 Cr FY24 [dir] — a marketing subsidiary, not the group P&L.

Do not contract the wrong CIN. If a later conversation happens, the manufacturing entity is United Biotech Private Limited (Baddi); Umano is only the Faridabad office and should stay out of Proof scope.

1.2 What they make & where money comes from

Products: 450+ SKUs claimed across six divisions (critical care, antibiotics/hormonals, oncology, GI/gynae, cardiology, nephrology; plus liposomal, ARV, mAbs). Manufacturing: injectables (dry powder, liquid, lyo), PFS, oral. UKMHRA / USFDA / TGA plus WHO-cGMP are company claims — confirm live inspection status before repeating.

Named customers / channels: AIIMS, PGI, Defence, Railways. Field force claimed 1,000+. Export names on site: Cuba (Eron), Argentina (Fada), Italy (Esseti, Kedrion, Hardis), Sweden (Recip). Export % not published. Import intensity unknown; sterile plants usually import filters, stoppers, lyo spares and some APIs [~].

Money: group operating revenue ₹100–500 Cr band FY24; Tofler headline ₹300–400 Cr with a 27% total-revenue increase and EBITDA up ~29% [dir]. Campaign brief uses ₹405–480 Cr [dir]. Umano IndiaMART copy still says parent “approx. 450 crores plus”. Use the range, not a single rupee figure, until MCA P&L is pulled.

1.2a Scale, MSME status & trade (mandatory from Aug 2026)

1.3 Plants, addresses & footprint

Which site does what: Baddi manufactures (injectables / lyo / PFS / oral, QC/QA labs). Faridabad Umano markets domestic healthcare SKUs. Delhi HO is commercial/export admin. Pilot site if they ever qualify: Baddi HT, not Plot 74.

1.4 Leadership & CRM map — three champion types (mandatory)

Decision path: Rajiv (or Ashwani/Sanjeev) says whether Baddi utilities may talk → Baddi E&I shares two HPSEBL bills → production/QA must not see Stamped as a batch-record risk. Plot 74 reception cannot sign a Proof. Site also names IBD/DRA staff (international@unitedbiotechindia.com) — not energy owners.

1.5 Recent news (24 months) & timing for Stamped

October 2025: Himachal monitoring authority expansion approvals named United Biotech Pvt. Ltd. [web] — a Baddi capex signal, not a Faridabad walk trigger. Baddi-Barotiwala-Nalagarh is under NGT/SPCB cluster scrutiny; that is regional, not a named United Biotech docket (§6.1). Timing: honest email now; Baddi only after a named utilities owner and two HT bills.

2. Energy profile

DISCOM / supply (name early): Faridabad Plot 74 is DHBVN (Dakshin Haryana Bijli Vitran Nigam) on an LT office account. Delhi HO is BSES. The factory is HPSEBL. Do not mix the three on one Proof scope.

2.1 Bill band, tariff & demand

Faridabad Plot 74: ₹0.3–1.5 lakh/month [~]. That is lighting, AC, IT and maybe a small UPS — Band B / skip for visit-week Proof. ₹30 lakh/month gate: No. Confidence: Low (no invoice). State it honestly: the Faridabad DHBVN bill is tiny; it is not a Stamped commercial object.

Baddi (the real bill, out of this week’s walk): sterile + HVAC + WFI + chilled water on a ~5 acre [~] WHO-cGMP site is typically high-teens to several-crore annual electricity, i.e. multiple lakh per month on HPSEBL HT [~] — do not invent a Baddi monthly figure. Qualify only with redacted HPSEBL invoices. PAT/DC status unknown.

ToD/PF/MD: relevant at Baddi; irrelevant theatre at Plot 74.

2.2 Generation, fuel & renewables

Unknown. Pharma plants in Baddi often have DG for GMP power continuity and sometimes boiler/steam for WFI stills. Rooftop solar possible, not advertised. Do not assume RE offsets MD.

2.3 EnMS, PAT, ISO, BRSR

ISO 9001:2015 and WHO-cGMP advertised. ISO 50001: absent (not found on site, LinkedIn, or Umano pages). No PAT DC listing found. No BRSR (unlisted private). Data maturity at Baddi unknown; Plot 74 will have no EMS.

2.4 Likely ₹ leak categories (hypothesis)

At Plot 74: after-hours AC and lighting. Not worth a Proof.

At Baddi (hypothesis only — not alleged):

1. HVAC / AHU left at production setpoint through idle batches.
2. WFI / purified-water loops 24×7 “for readiness”.
3. Chiller coincidence with filling-line start; lyo idle between cycles.
4. Compressed air left live; DG vs grid during testing.

Each needs interval data. None of this is visible from Sector 27-A.

3. Operations, equipment & digital stack

3.1 Process flow & critical loads

Baddi (public narrative): receipt / warehouse → dispensing → compounding → sterile filling / lyo / PFS / oral → QC/micro → packing → cold chain / dispatch. Critical electrical: HVAC, WFI, chillers, filling lines, lyophilisers, compressed air, purified water. Faridabad: desks, split AC, maybe a sample store. No filling.

3.1a Machine inventory (mandatory from Aug 2026)

Public evidence is process class, not OEM counts. Do not invent machine lists.

No CNC/VMC public. No Yaskawa / Inductotherm / Buhler. Filling-line OEMs (Bosch, IMA, etc.) not named on the public site.

3.2 Shifts, seasonality, production pattern

Sterile plants typically run campaign batches with validated cleaning windows. Export/tender peaks unknown. Faridabad office is day-shift. Do not baseline a Proof on office hours.

3.3 Automation, metering, SCADA/EMS/DCS

Umano site has an employee ERP login (umanohealthcare.in/erp) — commercial, not plant energy. Baddi likely has BMS/SCADA for HVAC (typical of WHO-cGMP); no named EMS vendor. Entry at Baddi would be Path A if BMS export exists, else Path B meter CSV. Plot 74 is Path-nothing.

3.4 Capex / tech projects affecting energy

HP expansion approval Oct 2025 [web] — ask what was added (new filling, new HVAC). Quarantine commissioning from any future baseline.

4. Stamped Energy fit analysis

4.1 ICP scorecard

4.2 Fit score rationale

5/10: group is large enough and Baddi process loads are real, but the Faridabad extras pin is the wrong building. Score is “do not waste the visit week; keep a Baddi intro in the CRM”. It is not a close forecast.

4.3 Wedge (parser-critical)

The strongest wedge is: do not walk Plot 74 as a factory; if Rajiv or Dr. Akshit will name a Baddi utilities owner, scope read-only metering on HPSEBL HVAC/WFI/chiller coincidence, assign one idle-cut with ₹ on WhatsApp, and keep it verified with evidence — and treat the Faridabad DHBVN office bill as out of scope.

4.4 Objections & competitors

“You are at the wrong address” — agree first. “We have WHO-cGMP / consultants” — Stamped is not a validation vendor. “ISO 9001 is enough” — ISO 50001 is absent; do not pretend they have an EnMS. “Send ESG” — refuse; plant ₹ at Baddi only. Competitors at Baddi: HVAC OEMs, energy auditors, maybe an EMS dashboard.

4.5 Pilot design

Visit week: no paid 60-Day Proof on Plot 74. Kill immediately if they insist the Faridabad office is the plant.

Later, Baddi only: one HPSEBL HT, 60 days, HVAC or chiller feeder, production/QA in the loop so no batch-risk Rx. Success: one owned action with verified ₹ movement. Kill: no named E&I, no bills, or demand to start at Plot 74.

4.6 Concern scores (1–10) and who owns them (mandatory from Aug 2026)

Scores are for Plot 74 / Faridabad pin, not the Baddi factory. Baddi would score higher on energy; we are not standing there this week.

4.7 Pitch sketches (draft — human will refine)

1. P&L / bill (Rajiv): United Biotech’s factory is Baddi, not Sector 27-A. I will not sell a 60-Day Proof on Umano’s DHBVN lighting bill. If Bagbania HVAC and WFI are a material HPSEBL line, we sit read-only on that meter, put rupee actions on WhatsApp, and keep the result verified with evidence. Early deployments elsewhere saw ~15–20% in weeks [~] — only where the HT band supports it. Two redacted Baddi bills decide whether we continue.

2. Maintenance (Baddi E&I, when named): This is not a dashboard for QA. It is which AHU, chiller or WFI still is still at production load after the batch stops. You already get night calls when a chiller trips. We assign one stagger or setpoint action with ₹ attached. You execute it. We do not write to the BMS.

3. Production (Baddi plant head, when named): We will not fight a sterile line. No Rx that risks differential pressure, WFI quality or batch release. The ask is idle utilities between campaigns, not cycle-time experiments. If production vetoes a card, it dies. Proof is on the meter ledger, not a yield argument.

5. Before you reach out

5.1 Discovery checklist

• Confirm Plot 74 is still Umano marketing/office (gate board).
• Do not treat two DHBVN bills as HT process accounts; they will show a tiny office lakh (or sub-lakh) number.
• Ask whether Baddi is HPSEBL HT and who owns that bill; E&I and plant head are search.
• USFDA/MHRA/TGA claim vs live; what the Oct 2025 HP expansion added.
• ISO 50001: treat as absent unless they produce a certificate.
• Umano vs UBPL contracting entity; whether Dr. Akshit is a useful CC.

5.2 Do not lead with

• Do not lead with a Faridabad factory walk, dashboards, AI, ESG, or “verified on the next DISCOM bill”.
• Do not lead with a 60-Day Proof price as if Plot 74 were LNM or a Baddi filling hall.
• Do not attach Baddi NGT cluster stories to this CIN without a named case.

5.3 Opening hooks (email / call / WhatsApp)

“Plot 74 is Umano’s office. I am not walking in expecting injectables. If Baddi utilities will look at two HT bills, we can talk read-only meters, rupees on WhatsApp, verified with evidence. If not, I’ll skip Faridabad.”

6. Risks, flags, controversies & sources

6.1 Integrity / controversy / regulatory (search explicitly)

Searched (Aug 2026): “United Biotech Pvt Ltd” / “United Biotech Baddi” + NGT, HSPCB, FDA warning letter, lawsuit, fraud, labour, tax raid (2024–2026). No company-named controversy hit found in this pass. Baddi pharma cluster is under long-running NGT/SPCB API-residue and CETP scrutiny (OA 801/2018 and related); recent named effluent notices in the belt (e.g. other units such as Biogenetic Drugs in press) are not this CIN. HP expansion approval Oct 2025 is a positive administrative mention, not a clean bill of health. None found against United Biotech as a named defendant in the search terms above. Do not allege.

6.2 Data quality flags

• Faridabad pin ≠ factory. Highest operational risk for visit week.
• Revenue ₹405–480 Cr vs Tofler ₹300–400 Cr vs IndiaMART “450 crores plus” — range only.
• Employee 150–200 vs 1,000+ field force — different populations.
• Rajiv email is HO inbox, not rajiv@.
• Baddi E&I and plant head unnamed.
• Filling-line OEMs unnamed; ~5 acre plot is [~].
• ISO 50001 absent; WHO-cGMP/USFDA language is company claim.

6.3 Sources consulted

• https://unitedbiotechindia.com and contact-us (HO, plant, Dr. Akshit, ho@, phones)
• https://umanohealthcare.com/contact-us/ (Plot 74, phones, info@umanohealthcare.com)
• Tofler CIN U24239DL1997PTC084814; IndiaMART Umano GST 06AABCU3733E1ZN / CIN U24297DL2011PTC227673
• LinkedIn company united-biotech-india-pvt-ltd-; Rajiv Kumar; Dr. Akshit Gakhar
• Himachal monitoring-authority expansion list (Oct 2025 news)
• NGT/HSPCB Baddi cluster context (not company-named)
• Campaign brief 16; ICP; messaging canon; DHBVN Faridabad industrial context
• Apollo: not used